Post by
etcetera on Jun 11, 2020 7:12am
WPD Pharmaceuticals clarifies WP1122 disclosure
The future looks quite promising for WPD1122
In an April 9, 2020, press release, WPD disclosed that independent research found 2-deoxy-D-glucose (2-DG) to reduce replication of SARS-CoV-2, the virus that causes COVID-19, by 100 per cent in in vitro testing.
2-DG is the active ingredient in WP1122.
WP1122 is referred to as a pro-drug of 2-DG whereby chemical elements are added to 2-DG to improve its delivery in vivo.
In a subsequent press release of the same date, WPD stated that the publication mentioned in its press release was a peer-reviewed scientific journal.
That reference was to the journal itself, but in the case of the preprint of the research that the company referred to in the NatureResearch on-line publication, it was specifically noted:
"Preprints are preliminary reports that have not undergone peer review.
They should not be considered conclusive, used to inform clinical practice or referenced by the media as validated information.
" The company now notes, however, that on May 14, 2020, this article was published in the journal Nature after undergoing peer review (D. Bojkova et al.,
Proteomics of SARS-CoV-2-infected host cells reveals therapy targets).
Regardless, readers are cautioned not to place undue reliance on in vitro data, which are not necessarily indicative of activity that may be seen in vivo.
https://www.stockwatch.com/News/Item?bid=Z-C%3aWBIO-2919386&symbol=WBIO®ion=C
Comment by
etcetera on Jun 11, 2020 8:46am
Well, the SARS-COV-2 seems to be a path to follow as there is another company that is working on it Recombinant SARS-CoV-2 Proteins Now Available For Research From ImmunoPrecise's European Subsidiary, UPE https://www.newswire.ca/news-releases/recombinant-sars-cov-2-proteins-now-available-for-research-from-immunoprecise-s-european-subsidiary-upe-874713834.html